Welcome to our dedicated page for Akoya BioSciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya BioSciences stock.
Akoya BioSciences, Inc. (Nasdaq: AKYA) is a leading life sciences technology company pioneering spatial biology solutions that transform discovery, clinical research, and diagnostics. Akoya is committed to advancing the science of imaging with its comprehensive platforms, including PhenoCycler® and PhenoImager®, that perform deep proteomic profiling and spatial phenotyping. These cutting-edge platforms enable researchers to analyze tissue samples with high precision, providing insights into cellular interactions and disease mechanisms.
In 2024, Akoya announced preliminary unaudited revenue for Q4 2023 between $25.5 million and $26.5 million, marking a significant increase from Q4 2022. For the fiscal year 2023, revenues are expected to reach between $95.6 million and $96.6 million.
Akoya's portfolio includes innovative products like PhenoCode™ Panels, PhenoCycler®, and PhenoImager® HT, which support high-throughput and high-parameter tissue analysis. Notably, the company has recently partnered with Thermo Fisher Scientific to enhance its spatial multiomic workflow by integrating ViewRNA technology.
The company's technology has attracted significant attention in the scientific community, with its systems cited in over 1,300 publications as of March 2024. Akoya has also formed strategic partnerships and collaborations, including with the Queensland Spatial Biology Centre and organizations like BostonGene and NeraCare, enhancing the application of its platforms in various fields of research and clinical diagnostics.
Financially, Akoya aims for substantial revenue growth in 2024 with projections exceeding 20%, supported by its robust balance sheet and strategic initiatives like the new Manufacturing Center of Excellence in Marlborough, MA. This facility is expected to streamline operations, improve supply chain efficiency, and meet the growing demand for spatial biology solutions.
If you're a scientist or software engineer passionate about revolutionizing imaging science, Akoya BioSciences offers an exciting environment for innovation. For more information, contact Akoya at info@akoyabio.com.
Akoya Biosciences (Nasdaq: AKYA) announced the shipment of its 1,000th instrument, marking a significant milestone and establishing the largest installed base in the spatial biology industry. This achievement highlights the widespread adoption of Akoya's technologies in research laboratories globally and sets the stage for clinical applications. The portfolio features advanced tools such as PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT, enabling precise spatial biomarker identification. CEO Brian McKelligon expressed gratitude to the team for their role in this success and reiterated the commitment to expanding their ecosystem of spatial biology solutions. The 1,000th system was delivered to iHisto, a histopathology lab known for high-quality services and innovative technologies.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCode Discovery Panels at the AACR 2023 Annual Meeting in Orlando, aimed at advancing cancer research. These panels facilitate the analysis of tumors and their microenvironment by providing ready-to-use biomarker combinations for immune profiling and tissue architecture assessment. They significantly reduce assay development time, accelerating spatial discovery by up to three times compared to traditional workflows. The company plans to expand its product offerings with more protein biomarker panels throughout 2023 and 2024, along with launching RNA panels in the latter half of 2023. Akoya's innovations aim to streamline workflows for researchers and enhance the capabilities of the PhenoCycler-Fusion platform.
FAQ
What is the current stock price of Akoya BioSciences (AKYA)?
What is the market cap of Akoya BioSciences (AKYA)?
What does Akoya BioSciences, Inc. do?
What are Akoya's core products?
How did Akoya perform financially in 2023?
Who are some of Akoya's key partners?
What recent achievements has Akoya announced?
How many publications have cited Akoya's technology?
What is Akoya's financial outlook for 2024?
What is the significance of the new Manufacturing Center of Excellence?
Who should consider working at Akoya BioSciences?
How can one contact Akoya BioSciences for more information?
